In this article, Walter Chalkley, Senior Editorial Project Manager for Cortellis Regulatory Intelligence, outlines the current situation with regard to the use of adjuvants in the influenza vaccine. Often, especially when a patient’s immune system is naive (as in paediatric patients) or undergoing senescence (the aging of the immune system in elderly patients), a heightened immune response is needed for a vaccine to have the desired effect. The addition of adjuvants to a vaccine is one way of doing this. The author explains that an adjuvanted seasonal influenza vaccine would be a major step in the US and that, despite the general concerns about adjuvants, developers see this area of unmet need as a potentially viable field of investigation.
https://www.jforcs.com/7/wp-content/uploads/2016/01/Adjuvanated….pdf